Mark DeLong - Aug 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Senior Vice President
Signature: /s/ David Watson, attorney-in-fact for Mark Delong
Stock symbol: APLS
Transactions as of: Aug 8, 2022
Transactions value $: -$244,900
Form type: 4
Date filed: 8/9/2022, 05:16 PM
Previous filing: Aug 8, 2022
Next filing: Aug 12, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$77.6K	+5K	+17.09%	$15.52	34.3K	Aug 8, 2022	Direct	F1
transaction	APLS	Common Stock	Sale	-$323K	-5K	-14.6%	$64.50	29.3K	Aug 8, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-5K	-33.33%	$0.00	10K	Aug 8, 2022	Common Stock	5K	$15.52	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale from an established 10B5-1 trading plan.
F2	This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.